Safety, Pharmacokinetics (PK) and Hemodynamic Effects of Ambrisentan in Single Ventricle Pediatric Patients
Phase of Trial: Phase II
Latest Information Update: 13 Sep 2019
Price : $35 *
At a glance
- Drugs Ambrisentan (Primary)
- Indications Congenital heart defects
- Focus Pharmacokinetics
- 20 Aug 2019 Status changed from active, no longer recruiting to completed.
- 14 Nov 2018 Results developing a population PK model by taking data from this trial, presented at the 91st Annual Scientific Sessions of the American Heart Association.
- 31 Aug 2018 Biomarkers information updated